This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shafee, N. Articles by Lee, E. Y-H. P. Search for Related Content PubMed PubMed Citation Articles by Shafee, N. Articles by Lee, E. Y-H. P.

Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53–Mediated Mouse Mammary Tumors

Departments of ¹ Microbiology and Molecular Genetics and ² Biological Chemistry and Developmental and Cell Biology, College of Medicine, University of California, Irvine, California; and Departments of ³ System Biology and ⁴ Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Eric J. Stanbridge, Department of Microbiology and Molecular Genetics, College of Medicine, University of California, Irvine, CA 92697. Phone: 949-824-7042; Fax: 949-824-2454; E-mail: ejstanbr{at}uci.edu, or Eva Y-H. P. Lee, Departments of Biological Chemistry and Developmental and Cell Biology, College of Medicine, University of California, Irvine, CA 92697. Phone: 949-824-9766; Fax: 949-824-9767; E-mail: elee{at}uci.edu.

Key Words: BRCA1 • DNA repair • breast cancer • cancer stem cells • chemoresistance

The majority of BRCA1-associated breast cancers are basal cell–like, which is associated with a poor outcome. Using a spontaneous mouse mammary tumor model, we show that platinum compounds, which generate DNA breaks during the repair process, are more effective than doxorubicin in Brca1/p53–mutated tumors. At 0.5 mg/kg of daily cisplatin treatment, 80% primary tumors (n = 8) show complete pathologic response. At greater dosages, 100% show complete response (n = 19). However, after 2 to 3 months of complete remission following platinum treatment, tumors relapse and become refractory to successive rounds of treatment. Approximately 3.8% to 8.0% (mean, 5.9%) of tumor cells express the normal mammary stem cell markers, CD29^hi24^med, and these cells are tumorigenic, whereas CD29^med24^–/lo and CD29^med24^hi cells have diminished tumorigenicity or are nontumorigenic, respectively. In partially platinum-responsive primary transplants, 6.6% to 11.0% (mean, 8.8%) tumor cells are CD29^hi24^med; these populations significantly increase to 16.5% to 29.2% (mean, 22.8%; P < 0.05) in platinum-refractory secondary tumor transplants. Further, refractory tumor cells have greater colony-forming ability than the primary transplant–derived cells in the presence of cisplatin. Expression of a normal stem cell marker, Nanog, is decreased in the CD29^hi24^med populations in the secondary transplants. Top2A expression is also down-regulated in secondary drug-resistant tumor populations and, in one case, was accompanied by genomic deletion of Top2A. These studies identify distinct cancer cell populations for therapeutic targeting in breast cancer and implicate clonal evolution and expansion of cancer stem-like cells as a potential cause of chemoresistance. [Cancer Res 2008;68(9):3243–50]

This article has been cited by other articles:

				F. Muggia BRCA-deficient animal models and cisplatin resistance Ann. Onc., May 1, 2009; 20(5): 962 - 962. [Full Text] [PDF]

				J. Fasano and F. Muggia Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann. Onc., April 1, 2009; 20(4): 609 - 614. [Abstract] [Full Text] [PDF]

				A. Magnifico, L. Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Menard, and E. Tagliabue Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab Clin. Cancer Res., March 15, 2009; 15(6): 2010 - 2021. [Abstract] [Full Text] [PDF]

				H. Korkaya and M. S. Wicha HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of Evil Clin. Cancer Res., March 15, 2009; 15(6): 1845 - 1847. [Abstract] [Full Text] [PDF]

				M. Luo, H. Fan, T. Nagy, H. Wei, C. Wang, S. Liu, M. S. Wicha, and J.-L. Guan Mammary Epithelial-Specific Ablation of the Focal Adhesion Kinase Suppresses Mammary Tumorigenesis by Affecting Mammary Cancer Stem/Progenitor Cells Cancer Res., January 15, 2009; 69(2): 466 - 474. [Abstract] [Full Text] [PDF]

				F. Vaillant, M.-L. Asselin-Labat, M. Shackleton, N. C. Forrest, G. J. Lindeman, and J. E. Visvader The Mammary Progenitor Marker CD61/{beta}3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis Cancer Res., October 1, 2008; 68(19): 7711 - 7717. [Abstract] [Full Text] [PDF]